Appendix C: Guidance for POC Diagnostic Testing for Influenza and COVID-19, 2021-2022

≥ 1 resident with signs & symptoms of upper respiratory tract infection (URI) / Influenza Like Illness (ILI)

Nasal swabs (2) for both SARS-CoV-2 rapid antigen and Rapid Influenza Diagnostic Antigen Tests (RIDT)

SARS-CoV-2 Pos / Flu Neg

- Consider molecular SARS-CoV-2 test for WGS
- Report case to LHD
- Manage facility per COVID-19 guidance:
  - Isolation/quarantine
  - Cohort based on COVID-19 status
  - SARS-CoV-2 response testing
  - SARS-CoV-2 treatment for positive residents and prophylaxis for exposed residents

SARS-CoV-2 Neg / Flu Pos

- Repeat flu test with molecular test for influenza typing (LHD, VBL, Priv. Contract Lab)
- Perform confirmatory molecular test for SARS-CoV-2
- Report case to LHD
- Manage facility per Flu guidance:
  - Cohort pos. flu residents
  - PPE per influenza recs
  - Influenza anti-viral treatment for positive residents or chemoprophylaxis for exposed residents

SARS-CoV-2 Pos / Flu Pos

- Repeat flu test with molecular test for typing (LHD, VBL, Priv. Contract Lab); consider molecular SARS-CoV-2 for WGS
- Manage residents per co-infection guidance:
  - Cohort within cohort; do NOT cross COVID-19 cohorts
  - PPE per COVID-19 recs
  - Treatment for positive residents, prophylaxis for exposed residents

SARS-CoV-2 Neg / Flu Neg

Cluster of Cases?
- YES
  - Molecular testing:
    - SARS-CoV-2 and Influenza tests AND
    - Full respiratory viral panel

- NO
  - Molecular testing:
    - SARS-CoV-2 and Influenza tests

1 WGS: whole genome sequencing  
2 LHD: local health department  
3 Treatment options for SARS-CoV-2 infection may include monoclonal antibody or antiviral drugs  
4 Post exposure prophylaxis (PEP) for SARS-CoV-2 may include monoclonal antibody  
5 VBL: Valencia Branch Lab  
6 CDPH Influenza Prevention and Management Guidance for SNF (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/SNF_DetectAndControlOutbreaks.aspx)